It has been estimated that 30% of medications are prescribed “off-label”, including many cancer drugs, and are frequently used by physicians even though they are not approved by theFDA for that particular purpose. Although ketamine has shown the potential to help millions of people find relief from the crushing effects of depression and neuropathic pain, pharmaceutical companies have been hesitant to invest the tens of millions of dollars required to fund the extensive and expensive clinical trial process necessary to get officialFDA approval. Since the drug is and will remain off-patent, no company can own the revenue stream.
Ketamine infusions are administered in a private office.